Literature DB >> 19199551

Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus.

Stan Deresinski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19199551     DOI： 10.1086/596630

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  20 in total

1.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

2.  Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.

Authors:  Sheila Adams-Sapper; Shantell Nolen; Grace Fox Donzelli; Mallika Lal; Kunihiko Chen; Livia Helena Justo da Silva; Beatriz M Moreira; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

3.  Ceftaroline-heteroresistant Staphylococcus aureus.

Authors:  Stephanie N Saravolatz; Hayley Martin; Joan Pawlak; Leonard B Johnson; Louis D Saravolatz
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

4.  Colistin heteroresistance in Enterobacter cloacae is associated with cross-resistance to the host antimicrobial lysozyme.

Authors:  Brooke A Napier; Victor Band; Eileen M Burd; David S Weiss
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Lateral transfer of genes and gene fragments in Staphylococcus extends beyond mobile elements.

Authors:  Cheong Xin Chan; Robert G Beiko; Mark A Ragan
Journal:  J Bacteriol       Date:  2011-05-27       Impact factor: 3.490

6.  Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Authors:  P Prokocimer; P Bien; J Surber; P Mehra; C DeAnda; J B Bulitta; G R Corey
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

7.  Frequent occurrence of trimethoprim-sulfamethoxazole hetero-resistant Staphylococcus aureus isolates in different African countries.

Authors:  C Coelho; H de Lencastre; M Aires-de-Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-03       Impact factor: 3.267

8.  Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus.

Authors:  R Banerjee; M G Fernandez; N Enthaler; C Graml; K E Greenwood-Quaintance; R Patel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-23       Impact factor: 3.267

9.  Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

Authors:  In-Gyu Bae; Jerome J Federspiel; José M Miró; Christopher W Woods; Lawrence Park; Michael J Rybak; Thomas H Rude; Suzanne Bradley; Suzana Bukovski; Cristina Garcia de la Maria; Souha S Kanj; Tony M Korman; Francesc Marco; David R Murdoch; Patrick Plesiat; Marta Rodriguez-Creixems; Porl Reinbott; Lisa Steed; Pierre Tattevin; Marie-Françoise Tripodi; Karly L Newton; G Ralph Corey; Vance G Fowler
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

10.  Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.

Authors:  David J Farrell; Rodrigo E Mendes; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.